Brokers Set Expectations for CRBU FY2024 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Brookline Capital Management upped their FY2024 earnings estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, November 6th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of ($1.66) for the year, up from their prior estimate of ($1.76). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.76) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q4 2024 earnings at ($0.39) EPS, FY2025 earnings at ($2.91) EPS and FY2027 earnings at ($3.80) EPS.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 43.47%.

A number of other brokerages also recently commented on CRBU. Royal Bank of Canada reiterated an “outperform” rating and issued a $14.00 target price on shares of Caribou Biosciences in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Tuesday, September 3rd.

Caribou Biosciences Trading Down 3.6 %

CRBU opened at $2.68 on Monday. The firm has a market cap of $242.16 million, a price-to-earnings ratio of -1.62 and a beta of 2.26. Caribou Biosciences has a 12 month low of $1.50 and a 12 month high of $8.33. The stock has a fifty day moving average price of $2.01 and a 200-day moving average price of $2.27.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently bought and sold shares of CRBU. Allspring Global Investments Holdings LLC raised its holdings in shares of Caribou Biosciences by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 42,653 shares of the company’s stock worth $219,000 after buying an additional 3,594 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Caribou Biosciences by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 230,192 shares of the company’s stock worth $1,097,000 after acquiring an additional 56,586 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Caribou Biosciences during the 1st quarter worth about $558,000. Entropy Technologies LP purchased a new stake in Caribou Biosciences during the 1st quarter valued at about $113,000. Finally, Vanguard Group Inc. raised its stake in shares of Caribou Biosciences by 3.8% in the first quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock worth $21,129,000 after purchasing an additional 148,751 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.